TARS

Tarsus Pharmaceuticals Inc

91.05

Sep 04 • 3:50 PM ET +7.85 (9.43%)

Healthcare Biotechnology USA Mid NASD

Today, 9:15 AMTarsus completes acquisition of Alkeus, gaining worldwide rights to Phase 3 Stargardt candidate gildeuretinol (ALK-001) for its eye-care pipeline

Peers: KRYS MIRM RYTM VKTX INCY BMRN AXSM MDGL KROS NBIX

| Held by: IWM VTI IWO VXF IBB PJP SCHA VTWO XPH IHE

Scroll to Statements

Index	RUT
Market Cap	4.00B
Enterprise Value	3.63B
Income	-46.48M
Sales	606.33M
Book/sh	8.01
Cash/sh	10.25
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	370
IPO	Oct 16, 2020

P/E	-
Forward P/E	54.90
PEG	-
P/S	6.59
P/B	11.36
P/C	8.89
P/FCF	71.35
EV/EBITDA	-
EV/Sales	5.99
Quick Ratio	3.17
Current Ratio	3.20
Debt/Eq	0.26
LT Debt/Eq	0.26
Option/Short	Yes / Yes

EPS (ttm)	-1.08
EPS next Y	1.66
EPS next Q	-1.42
EPS this Y	-30.37%
EPS next Y	180.01%
EPS next 5Y	-
EPS past 3/5Y	14.26% -3.80%
Sales past 3/5Y	159.54% -
EPS Y/Y TTM	53.58%
Sales Y/Y TTM	105.17%
EPS Q/Q	10.97%
Sales Q/Q	69.41%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-124.19% 2.51%

Insider Own	5.99%
Insider Trans	-5.96%
Inst Own	107.09%
Inst Trans	4.25%
ROA	-8.40%
ROE	-13.68%
ROIC	-10.67%
Gross Margin	93.28%
Oper. Margin	-8.00%
Profit Margin	-7.67%
SMA20	24.01%
SMA50	38.02%
SMA200	32.46%
Trades

Shs Outstand	43.27M
Shs Float	41.25M
Short Float	14.54%
Short Ratio	6.33
Short Interest	6.00M
52W High	85.25 6.80%
52W Low	48.20 88.90%
Volatility	5.00% 4.69%
ATR (14)	3.64
RSI (14)	84.49
Beta	0.45
Rel Volume	1.24
Avg Volume	947.90K
Volume	1,145,681

Perf Week	26.88%
Perf Month	39.37%
Perf Quarter	53.59%
Perf Half Y	24.28%
Perf YTD	11.20%
Perf Year	58.54%
Perf 3Y	446.52%
Perf 5Y	241.39%
Perf 10Y	-
Recom	1.00
Target Price	94.62
Prev Close	83.21
Price	91.05
Change %	9.43%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-24-26	Resumed	Oppenheimer	Outperform	$105 → $98
Dec-09-25	Initiated	Barclays	Overweight	$100
Nov-20-25	Initiated	Mizuho	Outperform	$100
Jun-02-25	Resumed	Oppenheimer	Outperform	$75
May-27-25	Resumed	H.C. Wainwright	Buy	$72
Nov-20-23	Initiated	Goldman	Neutral	$19
Jul-18-23	Initiated	William Blair	Outperform	$44
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight	$40
Dec-21-21	Initiated	H.C. Wainwright	Buy	$40
Nov-23-21	Initiated	Oppenheimer	Outperform	$55
Nov-10-20	Initiated	Raymond James	Strong Buy	$39
Nov-10-20	Initiated	Ladenburg Thalmann	Buy	$42
Nov-10-20	Initiated	Jefferies	Buy	$35
Nov-10-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Today 08:38AM	Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care (GlobeNewswire) +9.43%
Sep-01-26 04:30PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.76%
Aug-07-26 08:13AM	Tarsus joins Stargardt race to market with $800m Alkeus takeover (Pharmaceutical Technology)
Aug-06-26 03:02PM	Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ... (GuruFocus.com) +6.59%
10:07AM	Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M (BioPharma Dive)
07:03AM	Loading…
07:03AM	Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth (GlobeNewswire)
07:02AM	Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing (GlobeNewswire)
07:01AM	Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position (GlobeNewswire)
Aug-05-26 08:02PM	Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 (GlobeNewswire)
Jul-13-26 04:05PM	Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth (GlobeNewswire) -5.40%
Jul-10-26 04:04AM	ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership (BioPharma Dive) -9.35%
Jul-08-26 04:05PM	Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101 (GlobeNewswire) -5.30%
Jul-01-26 03:28PM	TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme (Stocktwits)
May-28-26 04:30PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-26 08:30AM	Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans (GlobeNewswire)
05:00PM	Loading…
May-07-26 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-06-26 08:37PM	Tarsus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby)
Apr-29-26 04:30PM	Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 (GlobeNewswire)
Mar-31-26 08:30AM	Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease (GlobeNewswire)
Mar-26-26 01:08PM	Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating (Investor's Business Daily)
Mar-23-26 08:30AM	TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus (GlobeNewswire)
Mar-06-26 10:22AM	Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating (Insider Monkey)
Mar-02-26 01:13PM	Maker Of Eye Drops Has Sights On Buy Point (Investor's Business Daily)
Feb-27-26 12:58PM	These Growth Stocks Form Classic Cup Bases. Here's Where To Buy. (Investor's Business Daily)
Feb-26-26 04:30PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-24-26 12:32PM	Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby) +7.79%
12:01AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2025 Earnings Call Highlights: Strong Financial ... (GuruFocus.com)
Feb-23-26 08:17PM	Tarsus Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
07:25PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
07:17AM	Loading…
Feb-20-26 07:17AM	Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q4 2025 Result (GuruFocus.com)
Feb-18-26 10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
08:30AM	Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors (GlobeNewswire)
Feb-17-26 04:30PM	Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026 (GlobeNewswire)
10:00AM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-02-26 12:27PM	Will Declining Medical Customers Affect Cigna's Q4 Earnings? (Zacks)
Jan-26-26 09:35AM	Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS) (Zacks)
Jan-13-26 11:40AM	BMRN or TARS: Which Is the Better Value Stock Right Now? (Zacks)
Nov-24-25 04:30PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-05-25 05:05PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire)
12:04AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-04-25 05:55PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Nov-03-25 07:31AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-28-25 05:00PM	Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire)
Oct-09-25 09:27AM	Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains? (Zacks)
Oct-06-25 06:41AM	Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last? (Zacks)
Aug-27-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 06:33PM	3 Biotech Catalysts Present Major Opportunity (MarketBeat)
Aug-15-25 10:04AM	This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine (Investor's Business Daily)
Aug-14-25 02:48PM	Lyme Disease Is Spiking. This Biotech Nears A Treatment And A Buy Point. (Investor's Business Daily)
Aug-06-25 06:00PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +15.15%
04:05PM	Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-05-25 09:48AM	Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result (GuruFocus.com)
Jul-30-25 05:00PM	Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 (GlobeNewswire)
May-29-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 09:45AM	Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-08-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
May-05-25 06:04PM	Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts (Insider Monkey)
May-02-25 03:17AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2025 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com) -5.84%
May-01-25 09:37PM	Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Apr-30-25 10:17AM	Will Declining Medical Customers Affect Cigna's Q1 Earnings? (Zacks)
09:55AM	Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High? (Zacks)
Apr-25-25 10:00AM	Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline (Zacks)
Apr-24-25 05:00PM	Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 (GlobeNewswire)
11:00AM	Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? (Zacks)
Apr-23-25 01:41PM	HCA Healthcare to Report Q1 Earnings: Key Estimates to Note (Zacks)
Apr-22-25 11:19AM	Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch (Zacks)
08:31AM	Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting (GlobeNewswire)
Apr-21-25 04:05PM	Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders (Business Wire)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-20-25 09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-12-25 09:49PM	Tarsus Announces Pricing of Upsized $125.0 Million Public Offering (GlobeNewswire)
04:12PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Mar-06-25 05:00PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire) +6.66%
Feb-26-25 02:13AM	Q4 2024 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:05AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Feb-25-25 08:40AM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.33%
07:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
01:31AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-20-25 05:00PM	Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 (GlobeNewswire)
Jan-30-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-20-25 03:31PM	Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Jan-14-25 09:35AM	Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround (Zacks) -5.72%
Jan-13-25 08:30AM	Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care (GlobeNewswire) -10.76%
Dec-26-24 10:30AM	How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run (Investor's Business Daily)
Dec-04-24 09:55AM	Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet (Zacks)
Nov-18-24 09:55AM	Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade (Zacks)
Nov-14-24 02:15AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-13-24 05:30PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
08:30AM	Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors (GlobeNewswire)
Nov-07-24 10:00AM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Nov-06-24 04:30PM	Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 (GlobeNewswire)
Nov-05-24 08:30AM	Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer (GlobeNewswire)
Oct-30-24 06:39AM	Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? (Zacks)
Oct-17-24 08:30AM	Tarsus Launches Your Mitey Problem, the First Direct-to-Consumer TV Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% (GlobeNewswire)
Oct-09-24 05:56PM	Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ... (GuruFocus.com)

Tarsus Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Co-FounderDr. Bobak R. Azamian M.D.

CFO & Chief Strategy OfficerMr. Jeffrey S. Farrow CPA

Chief Operating OfficerDr. Seshadri Neervannan Ph.D.

M.D.Dr. Bryan Wahl J.D.

Head of Investor RelationsMr. David Nakasone

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Neervannan Seshadri	Officer	Sep 04 '26	Proposed Sale	85.00	4,564	387,940		Sep 04 03:36 PM
Lin Elizabeth Yeu	Chief Medical Officer	Sep 02 '26	Sale	80.00	5,387	430,960	13,320	Sep 03 04:29 PM
Lin Elizabeth Yeu	Chief Medical Officer	Sep 01 '26	Sale	73.86	4,601	339,830	18,707	Sep 03 04:29 PM
Lin Elizabeth Yeu	Chief Medical Officer	Sep 02 '26	Sale	80.00	1,590	127,200	4,770	Sep 03 04:29 PM
Lin Elizabeth Yeu	Member of immediate family of	Sep 02 '26	Proposed Sale	80.00	1,590	127,200		Sep 02 04:31 PM
Mottiwala Aziz	Former Officer	Sep 02 '26	Proposed Sale	81.80	8,000	654,373		Sep 02 03:40 PM
Lin Elizabeth Yeu	Officer	Sep 02 '26	Proposed Sale	80.00	5,387	430,960		Sep 02 03:38 PM
BOBAK AZAMIAN	OFFICER	Sep 02 '26	Proposed Sale	80.06	10,000	800,569		Sep 02 02:39 PM
Mottiwala Aziz	Former Officer	Sep 01 '26	Proposed Sale	73.96	77,698	5,746,846		Sep 01 04:09 PM
Lin Elizabeth Yeu	Officer	Sep 01 '26	Proposed Sale	73.86	4,601	339,830		Sep 01 02:23 PM
Mottiwala Aziz	Former Officer	Aug 25 '26	Proposed Sale	71.85	81,332	5,843,887		Aug 25 04:19 PM
Mottiwala Aziz	Former Officer	Aug 19 '26	Proposed Sale	72.00	53,043	3,819,096		Aug 19 02:27 PM
Azamian Bobak R.	President/CEO and Board Chair	Jun 17 '26	Sale	61.55	10,000	615,488	847,991	Jun 22 04:09 PM
Farrow Jeffrey S	See Remarks	Jun 16 '26	Sale	60.95	14,396	877,436	56,801	Jun 17 04:17 PM
Goodrich Katherine	Director	Jun 15 '26	Sale	62.08	2,954	183,384	2,233	Jun 17 04:17 PM
LINK WILLIAM J PHD	Director	Jun 15 '26	Sale	62.12	12,500	776,495	106,786	Jun 17 04:17 PM
BOBAK AZAMIAN	OFFICER	Jun 17 '26	Proposed Sale	61.55	10,000	615,473		Jun 17 02:05 PM
Farrow Jeffrey S	Officer	Jun 16 '26	Proposed Sale	60.95	14,396	877,459		Jun 16 04:53 PM
William J Link	Director	Jun 15 '26	Proposed Sale	62.12	12,500	776,498		Jun 15 04:58 PM
Goodrich Katherine	Director	Jun 15 '26	Proposed Sale	62.08	2,954	183,384		Jun 15 11:44 AM
Neervannan Seshadri	Chief Operating Officer	Mar 20 '26	Sale	66.75	2,989	199,516	82,791	Mar 24 05:05 PM
Neervannan Seshadri	Officer	Mar 20 '26	Proposed Sale	66.75	2,989	199,516		Mar 20 10:38 AM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 18 '26	Sale	68.71	4,071	279,718	39,202	Mar 19 07:04 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 17 '26	Sale	69.42	4,029	279,693	43,273	Mar 19 07:04 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 19 '26	Sale	67.00	4,174	279,658	35,028	Mar 19 07:04 PM
Wahl Bryan	General Counsel	Mar 17 '26	Sale	69.42	4,084	283,511	72,315	Mar 19 07:04 PM
Wahl Bryan	General Counsel	Mar 19 '26	Sale	67.00	4,231	283,477	63,959	Mar 19 07:04 PM
Wahl Bryan	General Counsel	Mar 18 '26	Sale	68.71	4,125	283,429	68,190	Mar 19 07:04 PM
Neervannan Seshadri	Chief Operating Officer	Mar 19 '26	Sale	67.00	4,589	307,463	85,780	Mar 19 07:04 PM
Neervannan Seshadri	Chief Operating Officer	Mar 18 '26	Sale	68.71	3,610	248,043	90,369	Mar 19 07:04 PM
Neervannan Seshadri	Chief Operating Officer	Mar 17 '26	Sale	69.42	3,125	216,938	93,979	Mar 19 07:04 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 17 '26	Sale	69.42	4,286	297,534	70,250	Mar 19 07:04 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 18 '26	Sale	68.71	4,330	297,514	65,920	Mar 19 07:04 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 19 '26	Sale	67.00	4,440	297,480	61,480	Mar 19 07:04 PM
Lin Elizabeth Yeu	Chief Medical Officer	Mar 19 '26	Sale	67.00	390	26,130	23,308	Mar 19 07:04 PM
Lin Elizabeth Yeu	Chief Medical Officer	Mar 18 '26	Sale	68.71	379	26,041	23,698	Mar 19 07:04 PM
Lin Elizabeth Yeu	Chief Medical Officer	Mar 17 '26	Sale	69.42	375	26,032	24,077	Mar 19 07:04 PM
Farrow Jeffrey S	See Remarks	Mar 18 '26	Sale	68.71	2,133	146,558	45,502	Mar 19 07:03 PM
Farrow Jeffrey S	See Remarks	Mar 17 '26	Sale	69.42	2,111	146,546	47,635	Mar 19 07:03 PM
Farrow Jeffrey S	See Remarks	Mar 19 '26	Sale	67.00	2,186	146,462	43,316	Mar 19 07:03 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 18 '26	Sale	68.71	11,667	801,640	45,385	Mar 19 07:03 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 19 '26	Sale	67.00	11,964	801,588	33,421	Mar 19 07:03 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 17 '26	Sale	69.42	10,972	761,676	57,052	Mar 19 07:03 PM
Farrow Jeffrey S	Officer	Mar 19 '26	Proposed Sale	67.00	2,186	146,459		Mar 19 04:43 PM
Mottiwala Aziz	Officer	Mar 19 '26	Proposed Sale	67.00	4,440	297,475		Mar 19 04:38 PM
Azamian Bobak R.	Officer	Mar 19 '26	Proposed Sale	67.00	11,964	801,574		Mar 19 04:30 PM
Whitfield Dianne C.	Officer	Mar 19 '26	Proposed Sale	67.00	4,174	279,653		Mar 19 04:24 PM
Wahl Bryan	Officer	Mar 19 '26	Proposed Sale	67.00	4,231	283,472		Mar 19 04:23 PM
Neervannan Seshadri	Officer	Mar 19 '26	Proposed Sale	67.00	4,589	307,457		Mar 19 04:15 PM
Lin Elizabeth Yeu	Officer	Mar 19 '26	Proposed Sale	67.00	390	26,130		Mar 19 04:14 PM
Whitfield Dianne C.	Officer	Mar 18 '26	Proposed Sale	68.71	4,071	279,718		Mar 18 04:33 PM
Wahl Bryan	Officer	Mar 18 '26	Proposed Sale	68.71	4,125	283,428		Mar 18 04:18 PM
Azamian Bobak R.	Officer	Mar 18 '26	Proposed Sale	68.71	11,667	801,637		Mar 18 04:17 PM
Neervannan Seshadri	Officer	Mar 18 '26	Proposed Sale	68.71	3,610	248,042		Mar 18 04:17 PM
Farrow Jeffrey S	Officer	Mar 18 '26	Proposed Sale	68.71	2,133	146,558		Mar 18 04:14 PM
Mottiwala Aziz	Officer	Mar 18 '26	Proposed Sale	68.71	4,330	297,513		Mar 18 04:13 PM
Lin Elizabeth Yeu	Officer	Mar 18 '26	Proposed Sale	68.71	379	26,041		Mar 18 04:11 PM
LINK WILLIAM J PHD	Director	Mar 16 '26	Sale	68.79	12,500	859,819	116,332	Mar 18 04:11 PM
Azamian Bobak R.	Officer	Mar 17 '26	Proposed Sale	69.41	10,972	761,618		Mar 17 04:09 PM
Neervannan Seshadri	Officer	Mar 17 '26	Proposed Sale	69.41	3,125	216,921		Mar 17 04:07 PM
Farrow Jeffrey S	Officer	Mar 17 '26	Proposed Sale	69.41	2,111	146,534		Mar 17 04:03 PM
Wahl Bryan	Officer	Mar 17 '26	Proposed Sale	69.41	4,084	283,490		Mar 17 03:59 PM
Whitfield Dianne C.	Officer	Mar 17 '26	Proposed Sale	69.41	4,029	279,672		Mar 17 03:55 PM
Lin Elizabeth Yeu	Officer	Mar 17 '26	Proposed Sale	69.41	375	26,031		Mar 17 03:47 PM
Mottiwala Aziz	Officer	Mar 17 '26	Proposed Sale	69.41	4,286	297,511		Mar 17 03:42 PM
WILLIAM J LINK	DIRECTOR	Mar 16 '26	Proposed Sale	68.78	12,500	859,787		Mar 16 05:39 PM
Neervannan Seshadri	Chief Operating Officer	Mar 04 '26	Sale	76.67	8,366	641,421	70,817	Mar 05 04:03 PM
Neervannan Seshadri	Officer	Mar 04 '26	Proposed Sale	76.67	8,366	641,421		Mar 04 10:56 AM
Whitfield Dianne C.	Chief Human Resources Officer	Jan 02 '26	Sale	80.67	15,565	1,255,684	23,393	Jan 06 04:05 PM
Whitfield Dianne C.	Officer	Jan 02 '26	Proposed Sale	81.38	15,565	1,266,680		Jan 02 11:22 AM
Azamian Bobak R.	President/CEO and Board Chair	Dec 24 '25	Sale	82.51	6,000	495,089	857,991	Dec 30 04:26 PM
BOBAK AZAMIAN	OFFICER	Dec 24 '25	Proposed Sale	82.51	6,000	495,089		Dec 29 12:22 PM
Whitfield Dianne C.	Chief Human Resources Officer	Dec 16 '25	Sale	80.10	7,397	592,500	38,958	Dec 18 04:09 PM
LINK WILLIAM J PHD	Director	Dec 15 '25	Sale	81.43	12,500	1,017,816	128,832	Dec 17 04:07 PM
LINK WILLIAM J PHD	Director	Dec 15 '25	Sale	81.07	10,446	846,862	0	Dec 17 04:07 PM
Lin Elizabeth Yeu	Chief Medical Officer	Dec 16 '25	Sale	79.50	2,078	165,201	21,941	Dec 17 04:07 PM
Lin Elizabeth Yeu	Officer	Dec 16 '25	Proposed Sale	79.50	2,078	165,202		Dec 16 03:12 PM
Whitfield Dianne C.	Officer	Dec 16 '25	Proposed Sale	80.10	7,397	592,500		Dec 16 10:11 AM
William Link	Director	Dec 15 '25	Proposed Sale	81.02	10,446	846,340		Dec 15 04:38 PM
WILLIAM J LINK	DIRECTOR	Dec 15 '25	Proposed Sale	81.42	12,500	1,017,800		Dec 15 04:08 PM
Azamian Bobak R.	President/CEO and Board Chair	Sep 24 '25	Sale	55.37	6,000	332,220	812,106	Sep 26 04:08 PM
Bobak Azamian Living Trust	Officer	Sep 24 '25	Proposed Sale	55.37	6,000	332,208		Sep 24 04:57 PM
LINK WILLIAM J PHD	Director	Sep 08 '25	Sale	57.00	27,116	1,545,612	143,332	Sep 10 05:03 PM
LINK WILLIAM J PHD	Director	Sep 08 '25	Proposed Sale	57.01	27,116	1,546,000		Sep 08 04:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TARS

Tarsus Pharmaceuticals Inc

Upgrade your Finviz experience